Clinical trialNCT05786040RecruitingPhase 2Interventional

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

SponsorTimothy VoorheesEnrollment28Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Timothy J Voorhees, MD, MSCR
Ohio State University Comprehensive Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Joanna Rhodes, MD
Recruiting
University of North Carolina-Hillsborough Campus
Hillsborough, North Carolina, United States
Christopher E. Dittus, DO, MPH
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Timothy J. Voorhees, MD, MSCR
Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Narendranath Epperla, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Mar 2023
Primary completion: 31 Dec 2027
Completion: 31 Dec 2027
Last update posted: 14 Apr 2026
Registered enrollment: 28
Registry id: NCT05786040

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.